JP7357475B2 - Wet sheets and chemical solutions for wet sheets - Google Patents

Description

The present invention relates to wet sheets such as wet tissues and cleaning sheets, and chemical solutions for wet sheets.

Wet sheets (e.g., wet tissues, cleaning sheets, etc.), which are made by impregnating a fiber base material such as paper or non-woven fabric with a chemical solution mainly composed of water or hydroalcohol, are used to clean hands and bodies, as well as furniture, various equipment, floors, and toilets. It is widely used for purposes such as cleaning etc. In particular, in recent years, in response to increasing awareness of hygiene and beauty, various wet sheets have been proposed in which functional ingredients such as antibacterial ingredients, antiviral ingredients, and beauty ingredients such as collagen are added to the medicinal solution. .

As such a wet sheet, for example, Patent Document 1 proposes a powder preparation containing modified lysozyme and non-reducing sugar, and further describes a wet tissue using an alcohol solution (chemical solution) in which the powder preparation is dissolved. Further, Patent Document 2 proposes a wet tissue using an impregnating agent (chemical solution) containing collagen, silk oil, etc.

Japanese Patent Application Publication No. 2018-177712 Japanese Patent Application Publication No. 2001-000358

However, wet sheets in which proteins such as denatured lysozyme and collagen are added to the chemical solution locally change color to yellow or brown over time (hereinafter, such discoloration is referred to as "yellowing"). ) I had something to do.

SUMMARY OF THE INVENTION Therefore, the present invention provides a wet sheet in which a fiber base material is impregnated with a chemical solution containing protein, which does not easily yellow over time, and a chemical solution used in such a wet sheet. With the goal.

The present inventors conducted extensive research into the cause of the above-mentioned yellowing of wet sheets using chemical solutions containing proteins, and found that the water in the chemical solutions containing proteins evaporates over time, and in the process of evaporation. When the chemical solution locally gathers (liquid pools occur), the proteins in the chemical solution aggregate, and the aggregated proteins turn yellow due to the Maillard reaction, which is the cause of the yellowing of wet sheets as described above. I found out that it is.
Furthermore, the present inventors have conducted intensive studies on ways to suppress the yellowing of wet sheets using a chemical solution containing this protein, and have found that non-reducing sugars and moisturizing ingredients are added to the protein-containing chemical solution in specific amounts. By doing so, it is possible to reduce the water activity of the drug solution with non-reducing sugars, while suppressing the evaporation of water in the drug solution with the moisturizing ingredients, making it difficult to cause protein aggregation in the drug solution over time (i.e., protein The present inventors have discovered that the Maillard reaction due to aggregation can be made less likely to occur, and have completed the present invention.
The present invention includes the following aspects.

One aspect (aspect 1) of the present invention is a wet sheet formed by impregnating a fiber base material with a chemical solution containing protein,
The wet sheet is characterized in that the chemical solution further contains a non-reducing sugar and a moisturizing component in a content that satisfies the following formulas (1) and (2).
When 0.50≦Q _G <1.50, Q _T ≧4.00 (1)
When 1.50≦ _QG , _QT ≧0.30...(2)
Note that Q _T and Q _G in the formula each represent the content (mass %) of the non-reducing sugar and moisturizing component with respect to the mass of the entire drug solution.

In the wet sheet of this embodiment, the chemical solution contains proteins, non-reducing sugars, and moisturizing ingredients in the above-described specific contents. Since evaporation can be suppressed, aggregation of proteins in the chemical solution over time can be made less likely to occur.
As a result, in the wet sheet of this embodiment, the Maillard reaction due to protein aggregation is less likely to occur, and yellowing can be suppressed.

In another aspect (aspect 2) of the present invention, the wet sheet of aspect 1 is characterized in that the moisturizing component is glycerin.

In the wet sheet of this embodiment, since the moisturizing component is glycerin, the above-mentioned yellowing suppressing effect can be more effectively exhibited. In particular, when the non-reducing sugar is trehalose, the above-mentioned yellowing suppressing effect can be exhibited even more effectively.

In yet another aspect (aspect 3) of the present invention, in the wet sheet of aspect 1 or 2, the non-reducing sugar is trehalose.

In the wet sheet of this embodiment, since the non-reducing sugar is trehalose, the above-mentioned yellowing suppressing effect can be more effectively exhibited. In particular, when the moisturizing component is glycerin, the above-mentioned yellowing suppressing effect can be exhibited even more effectively.

In yet another aspect (aspect 4) of the present invention, in the wet sheet according to any one of aspects 1 to 3 above, the constituent fibers of the fiber base material are water-absorbing fibers.

If the constituent fibers of the fiber base material are water-absorbing fibers, the constituent fibers of the fiber base material will absorb water in the chemical solution, making it easier for proteins in the drug solution to aggregate and cause yellowing. The wet sheet can suppress yellowing even if the fiber base material is prone to yellowing, as the chemical solution contains non-reducing sugars and moisturizing ingredients in the above-specified amounts. .

In yet another aspect (aspect 5) of the present invention, in the wet sheet according to any one of aspects 1 to 4 above, the protein is denatured lysozyme.

Since the wet sheet of this embodiment uses modified lysozyme, which has excellent antiviral activity (especially anti-norovirus activity), as a protein contained in the drug solution, it can exhibit excellent antiviral activity as a wet sheet, and also has the above-mentioned properties. The non-reducing sugars and moisturizing ingredients make protein aggregation less likely to occur, making it possible to stably exhibit the antiviral activity evenly and over a long period of time.

In yet another aspect (aspect 6) of the present invention, in the wet sheet according to any one of aspects 1 to 5, the chemical solution contains at least one of polyaminopropyl biguanide or benzalkonium chloride.

In the wet sheet of this embodiment, the drug contains at least one of polyaminopropyl biguanide or benzalkonium chloride, and these ingredients have excellent antibacterial activity and safety for the human body, and are resistant to yellowing. As a sheet, it can exhibit excellent antibacterial activity, and the above-mentioned yellowing suppressing effect can also be exhibited more stably.

Yet another aspect (aspect 7) of the present invention is a chemical solution for wet sheets, comprising:
The medicinal solution is characterized in that it contains protein and further contains non-reducing sugar and a moisturizing component in a content that satisfies the following formulas (1) and (2).
When 0.50≦Q _G <1.50, Q _T ≧4.00 (1)
When 1.50≦ _QG , _QT ≧0.30...(2)
Note that Q _T and Q _G in the formula each represent the content (mass %) of the non-reducing sugar and moisturizing component with respect to the mass of the entire drug solution.

The chemical liquid for wet sheets of this embodiment contains protein, non-reducing sugars and moisturizing ingredients in the above-mentioned specific contents. Since the evaporation of the chemical can be suppressed, when it is applied as a chemical solution for a wet sheet, it can be made difficult to cause aggregation of proteins in the chemical solution over time.
Thereby, the chemical solution for wet sheets of the present embodiment can make it difficult for the Maillard reaction due to protein aggregation to occur in the wet sheets, thereby suppressing yellowing.

According to the present invention, a wet sheet in which a fiber base material is impregnated with a chemical solution containing protein can be made less likely to yellow even over time.

Hereinafter, preferred embodiments of the wet sheet of the present invention will be described in detail.

The wet sheet according to one embodiment of the present invention is a wet tissue in which a sheet-like fiber base material (for example, nonwoven fabric, etc.) is impregnated with a chemical solution mainly composed of water or hydroalcohol, and the wet sheet is one sheet or two sheets. A plurality of wet tissues as described above are stored in a folded state in a soft or hard airtight container.

Note that the airtight container for storing wet tissues is not particularly limited, and may include, for example, a container main body having liquid impermeability and gas barrier properties, a take-out port, and a soft or hard lid material that covers the take-out port so as to be openable and closable. It may be an airtight container that stores a plurality of wet tissues so that they can be taken out one by one, or it may be a flexible airtight packaging container that is made of a tearable sheet-like member and that stores wet tissues one at a time. There may be.

In the wet tissue of this embodiment, the chemical solution contains, in addition to water or hydroalcohol, enzymes such as proteolytic enzymes, denatured enzymes such as denatured lysozyme, collagen, silk protein (i.e., fibroin and It contains proteins such as sericin), and further contains non-reducing sugars such as trehalose and moisturizing ingredients such as glycerin in amounts that satisfy the following formulas (1) and (2).
When 0.50≦Q _G <1.50, Q _T ≧4.00 (1)
When 1.50≦ _QG , _QT ≧0.30...(2)
Note that Q _T and Q _G in the formula each represent the content (mass %) of the non-reducing sugar and moisturizing component with respect to the mass of the entire drug solution.

In the wet tissue of this embodiment, the medicinal solution contains proteins, non-reducing sugars, and moisturizing ingredients in the above-described specific contents, and the non-reducing sugars reduce the water activity of the medicinal solution (i.e., the water content in the medicinal solution is reduced). Moisturizing ingredients can suppress the evaporation of water in the drug solution (while increasing the viscosity and reducing the fluidity of the drug solution itself), making it difficult for proteins in the drug solution to aggregate over time. .
As a result, in the wet tissue of this embodiment, the Maillard reaction due to protein aggregation is less likely to occur, and yellowing can be suppressed.

In addition, in the present invention, it is more preferable that the drug solution contains the above-mentioned non-reducing sugar and moisturizing component together with protein in a content that satisfies the following formula (1') or formula (2').
When 1.00≦Q _G <1.50, Q _T ≧5.00 (1')
When 1.50≦ _QG , _QT ≧0.35...(2')

If a drug solution containing protein contains non-reducing sugars and moisturizing ingredients at a specific content that satisfies formula (1') or formula (2'), the aggregation of proteins in the drug solution over time will be prevented. It is possible to further reliably reduce the occurrence of yellowing, that is, it is possible to further reliably suppress yellowing of wet tissues.

In addition, the wet tissue of the above-mentioned embodiment can be used not only at room temperature (20° C.±15° C.), but also after being heated with a heating device or a heat-retaining device.
Further, the wet sheet of the present invention is not limited to the wet tissue as in the above-described embodiment, but may also be a cleaning sheet used for wiping floors and toilets, etc., for example.

Hereinafter, various members and components constituting the wet sheet of the present invention will be explained in more detail.

[Fiber base material]
The fiber base material used in the wet sheet of the present invention is not particularly limited as long as it has various properties (e.g., liquid retention, wipeability, texture, wet strength, etc.) that can be used as a fiber base material for a wet sheet. Any sheet-like fiber base material made of natural fibers or chemical fibers (that is, synthetic fibers, semi-synthetic fibers, recycled fibers, etc.), such as nonwoven fabrics, paper, woven fabrics, knitted fabrics, etc., can be employed. Among these, it is preferable to use nonwoven fabric or paper as the fiber base material in terms of ease of absorbing and retaining the chemical solution and ease of wiping it off.

When using a nonwoven fabric as a fiber base material, the type is not particularly limited, and any nonwoven fabric manufactured by a known method such as a dry method, a wet method, a water jet method, a spunbond method, an air laid method, a needle punch method, a felt method, etc. Nonwoven fabrics (for example, spunlace nonwoven fabrics, air-through nonwoven fabrics, spunbond nonwoven fabrics, point bonded nonwoven fabrics, etc.) can be employed. Among these, spunlace nonwoven fabric with high wet strength can be preferably used.

Further, when paper is used as the fiber base material, the type thereof is not particularly limited, and any paper made using various paper screens may be employed.

The fibers constituting the fiber base material (constituent fibers) are not particularly limited as long as they can constitute the fiber base material of the wet sheet, and examples include cellulose fibers and synthetic fibers.

Furthermore, examples of cellulose fibers include natural cellulose fibers such as pulp, cotton, and hemp; and regenerated cellulose fibers such as rayon, lyocell, and cupra. It may be used alone or in combination of two or more types of fibers.

Synthetic fibers include polyester fibers such as polyethylene terephthalate (PET) and polytrimethylene terephthalate (PTT); polyolefin fibers such as polyethylene (PE) and polypropylene (PP); polyvinyl alcohol fibers such as vinylon; Examples include polyacrylic fibers such as acrylonitrile; polyurethane (PU) fibers; and polyamide fibers such as nylon. These synthetic fibers can be used alone or in combination of two or more types. You may.
Note that the form of the synthetic fiber is not particularly limited, and for example, PP (core)/PE (sheath), high melting point PP (core)/low melting point PP (sheath), PET (core)/PE ( Synthetic fibers in any form can be used, such as core-sheath type composite fibers such as sheath parts); side-by-side type composite fibers; fibers with irregular cross sections such as flat, Y-shaped, and C-shaped.

Among these fibers mentioned above, it is preferable to use cellulose fibers such as natural cellulose fibers and regenerated cellulose fibers because they have high hydrophilicity and water retention.Furthermore, they have excellent texture and moisture absorption, and are resistant to heat. It is particularly preferable to use rayon because it is strong.
Note that the cellulose fibers are preferably contained in the fiber base material in a proportion of 40% by mass or more based on the mass of the entire constituent fibers. When the cellulose fiber is contained in a proportion of 40% by mass or more, there is an advantage that the fiber base material absorbs and retains the chemical solution easily.

Furthermore, the constituent fibers of the fiber base material may contain arbitrary functional ingredients such as antibacterial agents and cosmetic ingredients.

Further, in the wet sheet of the present invention, the constituent fibers of the fiber base material are preferably water-absorbing fibers such as cellulose fibers and acrylic fibers modified with polyacrylate. When the constituent fibers of the fiber base material are water-absorbing fibers, the constituent fibers of the fiber base material usually absorb water in the chemical solution, which tends to cause the proteins in the drug solution to aggregate and cause yellowing. The wet sheet of the present invention can suppress yellowing even if the fiber base material is prone to such yellowing because the chemical solution contains non-reducing sugar and moisturizing ingredients in the above-mentioned specific contents. I can do it.
In addition, even in such water-absorbing fibers, since the fiber base material easily absorbs and retains chemical solutions, it is contained in the fiber base material at a ratio of 40% by mass or more based on the mass of the entire constituent fibers. It is preferable.

In the present invention, the structure of the fiber base material is not particularly limited, and the fiber base material may have a single layer structure consisting only of fiber layers such as the above-mentioned nonwoven fabric, or a multilayer structure in which multiple types of fiber layers are laminated. It may have a structure.

In the present invention, the external shape of the fiber base material is not particularly limited as long as it has a sheet-like structure that can be used as a fiber base material of a wet sheet, and examples include rectangular, square, circular, and elliptical shapes. Any external shape can be adopted.
Furthermore, the surface structure of the fiber base material is not particularly limited, and may have a sheet-like structure with flat surfaces on both sides, a mesh-like structure, an uneven structure, or a porous structure having a plurality of openings.

Furthermore, the size and basis weight of the fiber base material are not particularly limited, and may be any size (for example, 200 mm x 150 mm) or basis weight (for example, 1 sheet 20 g/m ² to 100 g/m ² ) can be adopted.

Next, the chemical solution used in the wet sheet of the present invention will be explained.

[Medicinal solution]
The chemical solution used in the wet sheet of the present invention is mainly water or hydroalcohol, contains proteins such as functional ingredients such as denatured lysozyme, collagen, and silk protein (i.e., fibroin and sericin), and also contains non-reducing sugars and It further contains a moisturizing component in a specific content that satisfies the above formulas (1) and (2).

The water or hydrous alcohol used as the main component of the chemical solution is not particularly limited, and any known water or hydrous alcohol used in the chemical solution for wet sheets can be employed. Examples of such water include purified water that has passed through an ion exchange membrane, etc., and examples of hydrous alcohols include the above water, lower alcohols such as ethanol and isopropanol, and higher alcohols such as isostearyl alcohol. Examples include those containing.
Among these, water-containing ethanol containing water and ethanol can be preferably used from the viewpoint of sterilizing properties, wiping properties, and the like.

Note that when the chemical solution contains only water as a main component, the content of water in the chemical solution is preferably within the range of 90.00% by mass to 98.20% by mass based on the mass of the entire chemical solution. In addition, when the chemical solution contains hydrous alcohol as a main component, the content of water in the chemical solution is preferably within the range of 10.00% by mass to 88.20% by mass based on the mass of the entire drug solution. The content of alcohol in the drug is preferably within the range of 10.00% by mass to 88.20% by mass based on the mass of the entire chemical solution.

(protein)
The drug solution used in the present invention contains protein as a functional component. The protein used in the present invention is not particularly limited as long as it can be used as a functional component of wet sheets (e.g., antibacterial component, antiviral component, beauty component, etc.). Examples include denatured enzymes such as lysozyme, proteins such as collagen, silk protein (i.e., fibroin and sericin), and elastin.These proteins can be used alone or in combination with two or more proteins. It's okay.

Among these, in the wet sheet of the present invention, it is preferable to use an enzyme or a denatured enzyme as the protein contained in the chemical solution, and it is particularly preferable to use a denatured lysozyme. When modified lysozyme, which has excellent antiviral activity (especially anti-norovirus activity), is used as a protein contained in the drug solution, it can exhibit excellent antiviral activity as a wet sheet, and the non-reducing sugar and moisturizing ingredients mentioned above Since protein aggregation is less likely to occur, such antiviral activity can be exhibited evenly and stably for a long period of time.

In this specification, modified lysozyme refers to lysozyme whose three-dimensional structure has changed, and specifically, the original three-dimensional structure of lysozyme has changed, resulting in fluorescence, which is an indicator of surface hydrophobicity. It refers to something whose intensity has changed to 4,000 or more.
Here, the fluorescence intensity can be measured by the following method based on the method described in Canadian Institute of Food Science and Technology 1985 Vol. 18 No. 4, p. 290-295.

(Method of measuring fluorescence intensity)
First, the diluted solution was diluted with a phosphate buffer (pH 7.0) so that the concentration of denatured lysozyme was 0.05% by mass in terms of solid content and the concentration of phosphate was 0.2M. obtain. Furthermore, a solution obtained by adding 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid to 5 mL of the obtained diluted solution was reacted for 30 minutes at a temperature of 20°C or higher and 25°C or lower (room temperature). After that, the fluorescence intensity of the liquid at a wavelength of 470 nm (fluorescence band width of 10 nm) is measured under conditions of an excitation wavelength of 390 nm (excitation band width of 10 nm).
The fluorescence intensity was measured separately using the fluorescence intensity of a 0.2M phosphate buffer (pH 7.0, containing sodium dihydrogen phosphate and disodium hydrogen phosphate as phosphates) as a blank value. The value obtained by subtracting the value will be adopted.

In the present invention, when denatured lysozyme is used as the protein contained in the drug solution, the denatured lysozyme preferably has the above-mentioned fluorescence intensity of 4,500 or more, from the viewpoint of obtaining superior anti-norovirus activity. 000 or more is more preferable. Further, the upper limit of the fluorescence intensity of modified lysozyme is not particularly limited, and for example, a fluorescence intensity of 10,000 or less can be adopted.

Examples of modified lysozyme that can be used in the present invention include any modification of lysozyme such as egg white lysozyme by heat treatment, acid treatment, alkali treatment, enzyme treatment, organic solvent treatment, oxidation treatment, reduction treatment, high pressure treatment, etc. Examples include those modified by processing, and specifically, those disclosed in JP 2018-177712, JP 2016-34939, Japanese Patent No. 5806434, etc. can be suitably used. .

Further, the content of protein in the drug solution is not particularly limited, and for example, a content within the range of 0.05% by mass to 5.00% by mass based on the mass of the entire drug solution can be adopted, and is preferably The content is within the range of 0.10% by mass to 3.00% by mass.

(non-reducing sugar)
Furthermore, the drug solution used in the present invention contains a non-reducing sugar in order to reduce the water activity in the drug solution, that is, to increase the viscosity of the water in the drug solution and reduce the fluidity of the drug solution itself.
Here, the term "non-reducing sugar" refers to a sugar that does not exhibit reducing properties, and is a sugar that has lost its reducing properties due to a reducing monosaccharide bonding with another sugar through a glycosidic bond or the like. Note that non-reducing sugars are sugars that do not participate in the Maillard reaction described above.

Examples of non-reducing sugars that can be used in the present invention include trehalose (α,α-trehalose), neotrehalose (α,β-trehalose), isotrehalose (β,β-trehalose), disaccharides such as sucrose, raffinose, etc. These non-reducing sugars include polysaccharides such as trisaccharides, α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. May be used together.

Among these, in the wet sheet of the present invention, it is preferable to use a non-reducing sugar contained in the chemical solution that exhibits good solubility in water and hydrous alcohol, which are the main components of the chemical solution, and in particular, trehalose is used. It is preferable. By using trehalose as a non-reducing sugar, the above-mentioned yellowing suppressing effect can be more effectively exerted.Especially, when glycerin is a moisturizing ingredient added to the drug solution together with the non-reducing sugar, the above-mentioned The yellowing suppressing effect can be exhibited even more effectively.

The content of non-reducing sugar in the medicinal solution is determined by the relationship with the content of moisturizing ingredients, and specifically, the content satisfies the above formula (1) or (2), and preferably the content satisfies the above formula (1) or (2). The content satisfies formulas (1') to (2'). That is, the non-reducing sugar can be contained in the drug solution at a ratio of 0.30% by mass or more based on the mass of the entire drug solution, and the upper limit is not particularly limited, but from the viewpoint of solubility etc., it may be, for example, 20%. It is 0% by mass or less.

(moisturizing ingredient)
Further, the chemical solution used in the present invention contains a moisturizing component in order to suppress evaporation of water in the drug solution.
Examples of moisturizing ingredients that can be used in the present invention include polyhydric alcohols such as glycerin, polyethylene glycol, propylene glycol, 1,3-butylene glycol, dipropylene glycol, and sorbitol. These components may be used alone, or two or more components may be used in combination.

Among these, in the wet sheet of the present invention, it is preferable to use glycerin as a moisturizing component contained in the chemical solution. By using glycerin as a moisturizing ingredient, the above-mentioned yellowing suppressing effect can be more effectively exerted.Especially, when the non-reducing sugar added to the drug solution together with the moisturizing ingredient is trehalose, the above-mentioned yellowing suppressing effect can be more effectively exerted. It is possible to exhibit the effect of suppressing changes even more effectively.

The content of the moisturizing component in the medicinal solution is a content that satisfies the above formulas (1) to (2), preferably a content that satisfies the above formulas (1') to (2'). That is, the moisturizing component can be contained in the drug solution at a ratio of 0.50% by mass or more based on the mass of the entire drug solution, and the upper limit is not particularly limited, but from the viewpoint of solubility etc., it is, for example, 40.0% by mass or more. mass% or less.

(Other ingredients)
Furthermore, the chemical solution used in the present invention may contain other components other than the above-mentioned proteins, non-reducing sugars, and moisturizing components, as long as they do not impede the effects of the present invention. Such other ingredients include, for example, methylparaben, ethylparaben, benzoic acid, sodium benzoate, iodopropynyl butylcarbamate (IPBC), polyaminopropyl biguanide, benzalkonium chloride, cetylpyridinium chloride, ethylenediaminetetraacetic acid diacetate. Preservatives such as hydrogen disodium (EDTA-2Na); pH adjusters such as citric acid, sodium citrate, sodium hydroxide, and triethanolamine; antioxidants such as tocopherol acetate; carboxyvinyl polymers, hydroxyethyl cellulose, etc. Thickeners; surfactants such as glycerin fatty acid esters and sucrose fatty acid esters; amino acids with antibacterial properties such as glycine and alanine; antibacterial agents derived from natural products such as tea extracts and bamboo extracts; pigments; cleaning agents; Anti-inflammatory agents; refreshing agents; fragrances, etc. may be mentioned, and these ingredients may be used alone or in combination of two or more types.

Among these, the wet sheet of the present invention preferably contains at least one preservative of polyaminopropyl biguanide or benzalkonium chloride as another component contained in the chemical solution. These ingredients have excellent antibacterial activity and safety for the human body, and are resistant to yellowing, so they can exhibit excellent antibacterial activity as a wet sheet, and the above-mentioned yellowing suppression effect is also more stable. and can demonstrate it.
In addition, it is particularly preferable that both of these components are included.

Further, the content of other components is not particularly limited as long as it does not impair the effects of the present invention, and is, for example, 1.00% by mass or less, preferably 0.50% by mass or less based on the mass of the entire drug solution. The content is more preferably 0.10% by mass or less. In addition, when the other components are a plurality of components, the above content means the total content of the plurality of components.

In the present invention, the amount of the chemical solution impregnated into the fiber base material is not particularly limited, and is preferably 150 parts by mass to 400 parts by mass (that is, an impregnation rate of 150% to 400%) per 100 parts by mass of the fiber base material. It is possible to impregnate 200 parts by mass to 300 parts by mass of a chemical solution (ie, an impregnation rate of 200% to 300%).

The wet sheet of the present invention is a wet tissue or cleaning sheet used for purposes such as cleaning hands and bodies, cleaning furniture, various equipment, floors, toilets, etc. in homes, workplaces, medical institutions, etc. It can be particularly suitably used as

The wet sheet of the present invention is not limited to the embodiments described above or the examples described below, and can be appropriately combined, substituted, and changed within the scope of the purpose and gist of the present invention.

Hereinafter, the present invention will be explained in more detail by illustrating Examples and Comparative Examples, but the present invention is not limited only to these Examples.

Examples 1 to 10
Aqueous ethanol with a blending ratio of ethanol and water (ethanol/water) of 50% by mass/50% by mass, heat-denatured lysozyme as a protein component (manufactured by Kewpie Corporation, product name "Noro Clear Protein"), and non-reduced Trehalose (manufactured by Hayashibara Co., Ltd., trade name "Treha") as a sugar component and glycerin (manufactured by Sakamoto Pharmaceutical Co., Ltd., concentrated glycerin) as a moisturizing component were added and stirred to form the wet sheet of Example 1. Obtained drug solution. The specific content of each component in the drug solution is shown in Table 1 below.
In addition, chemical solutions for wet sheets of Examples 2 to 10 were obtained in the same manner as in Example 1, except that the contents of each component in the chemical solutions were changed to those shown in Table 1 below.

Examples 11-14
In addition, the protein components were changed to silk protein (manufactured by Seiwa Kasei Co., Ltd., Promois SILK-1000), collagen (manufactured by Nitta Gelatin Co., Ltd., TYPE-S), and elastin (manufactured by Koken Co., Ltd., Elas Ocean). The chemical solutions for wet sheets of Examples 11 to 14 were obtained in the same manner as in Example 7, respectively.

Comparative examples 1 to 7
In addition, as a comparative example of the present invention, each comparison was made in the same manner as in Example 1, except that the contents of the non-reducing sugar component and the moisturizing component did not satisfy the above formulas (1) and (2). Chemical solutions for wet sheets of Examples 1 to 7 were obtained. The specific content of each component in the drug solution is shown in Table 2 below.

The resulting chemical solutions of Examples 1 to 14 and Comparative Examples 1 to 7 were evaluated for the occurrence of yellowing according to the <yellowing evaluation method> below. The evaluation results are shown in Tables 1 and 2 below. In addition, the numerical value in parentheses in the yellowing evaluation result column in each table represents the incidence of yellowing.

<Yellowing evaluation method>
(1) Pour 1 g (0.97 g to 1.03 g) of raw rayon cotton into a colorless and transparent wide-mouthed bottle (As One standard bottle No. 4 (5-130-03), material: soda lime glass, cutting capacity: 37. 5 mL).
(2) Drop 2.7 g of the drug solution to be evaluated into the bottle. Note that the chemical solution is poured into the bottle while being dripped onto the contact area between the raw rayon cotton and the inner surface of the bottle.
(3) Cover the mouth of the bottle with cling film to prevent wrinkles, and secure with a rubber band to prevent the film from coming off.
(4) Six ventilation holes are formed in the wrap film covering the mouth of the bottle to obtain a sample bottle for yellowing evaluation.
(5) By carrying out the steps (1) to (4) above using the same chemical solution, 30 sample bottles for yellowing evaluation are prepared.
(6) Place multiple sample bottles into a warming machine set at a temperature of 50°C to 60°C.
(7) Visually inspect multiple sample bottles placed in a warming machine every other day for 7 days to check for yellowing.
(8) Calculate the yellowing incidence rate (%) of the chemical solution by counting the number of sample bottles in which yellowing has occurred and dividing by the number of all sample bottles.
(9) Evaluate the incidence of yellowing of the chemical solution based on the following criteria.
Yellowing incidence rate is 10% or less: ◎ (yellowing hardly occurs)
Yellowing incidence rate is over 10% and 30% or less: ○ (yellowing is unlikely to occur)
Yellowing incidence rate is over 30%: × (yellowing is likely to occur)

As shown in Tables 1 and 2, the medicinal solutions of Examples 1 to 14 containing protein, non-reducing sugars, and moisturizing ingredients at specific contents that satisfy the above formulas (1) and (2) are yellow in color. It was found that all of the chemical solutions of Comparative Examples 1 to 7, which did not contain specific amounts of non-reducing sugar and moisturizing ingredients, were more likely to cause yellowing. Ta.

Example 15
Furthermore, in water-containing ethanol, heat-denatured lysozyme (manufactured by Kewpie Corporation, trade name "Noro Clear Protein") as a protein component, and trehalose (manufactured by Hayashibara Co., Ltd., trade name "Treha") as a non-reducing sugar component, Glycerin as a moisturizing ingredient, polyaminopropyl biguanide (manufactured by Lonza Japan Co., Ltd., COSMOCIL CQ) and benzalkonium chloride (manufactured by NOF Corporation, Nissan Cation F2-50R) as preservatives were added and stirred. A chemical solution for wet sheets of Example 15 was obtained. The specific content of each component in the drug solution is shown in Table 3 below.
In addition, by carding raw cotton of rayon (manufactured by Daiwabo Rayon Co., Ltd., fineness: 1.44 dtex, fiber length: 44 mm) to create a fiber web, and spraying a jet water stream onto the fiber web, A spunlace nonwoven fabric was produced by entangling the fibers in the fibrous web with a high-pressure water stream. Furthermore, this spunlace nonwoven fabric was cut into a predetermined size (135 mm x 190 mm) to obtain a fiber base material for a wet sheet.

First, the obtained chemical solution of Example 15 was evaluated for the occurrence of yellowing according to the above-mentioned <yellowing evaluation method>. The evaluation results are shown in Table 3 below.
Furthermore, by impregnating the above fiber base material with the chemical solution of Example 15 at five types of impregnation rates (i.e., 250%, 260%, 270%, 280% and 290%), five types of chemicals with different impregnation rates were obtained. A wet sheet was made. Note that three of these five types of wet sheets having different impregnation rates were produced for each impregnation rate.
For the five types of wet sheets with different impregnation rates obtained in this way, the number of viruses reduced after wiping was measured according to the <Antiviral test method> below, and the antiviral properties for each impregnation rate were evaluated. did. Furthermore, similar tests were conducted on wet sheets that had been stored at 50°C to 60°C for one month.
The results of these antiviral tests are shown in Tables 4 and 5 below. Table 4 shows the antiviral test results of the wet sheet before storage at 50°C to 60°C for one month, and Table 5 shows the results of the antiviral test of the wet sheet after storing it at 50°C to 60°C for one month. These are the antiviral test results.

<Antiviral test method>
(1) Drop 1.0 mL of mouse norovirus (MNV) suspension onto a dry heat sterilized stainless steel plate (10 cm x 20 cm), spread it over the entire stainless steel plate using a platinum loop, and air dry until completely dry. do.
(2) After drying, the area where the MNV suspension was dropped was wiped back and forth 10 times with a sheet (wet sheet) to be evaluated, and left to stand for 5 seconds.
(3) Then, drop 10 mL of phosphate buffered saline (PBS) onto a stainless steel plate, collect the entire volume while pipetting, and perform a plaque assay as a 10-fold dilution to determine the infectious titer remaining on the plate. Measure.
(4) Furthermore, the wiped sheet is placed in a stomacher bag, and after 60 seconds, 10 mL of PBS is added to perform stomacher treatment. A plaque assay is performed using a 10-fold dilution of the solution to measure the infectious titer remaining on the sheet.

As shown in Tables 3 to 5, the wet sheet impregnated with the chemical solution of Example 15 is an excellent anti-norovirus wet sheet because it uses modified lysozyme, which has excellent anti-norovirus activity, as a protein contained in the drug solution. It was found that it can exhibit activity. Furthermore, this wet sheet has a chemical solution that contains non-reducing sugars and moisturizing ingredients in specific amounts that satisfy the above formulas (1) and (2), making it difficult for modified lysozyme to aggregate. It was found that even after the sheet was stored at 50°C to 60°C for one month, it did not yellow and the anti-norovirus activity could be maintained at the same level as before storage.

Claims (6)

A wet sheet made of a fiber base material impregnated with a chemical solution containing protein,
The medicinal solution further contains non-reducing sugar and a moisturizing ingredient in a content that satisfies the following formula (1) or formula (2),
The wet sheet, wherein the protein is denatured lysozyme .
When 0.50≦Q _G <1.50, Q _T ≧4.00 (1)
When 1.50≦ _QG , _QT ≧0.30...(2)
Note that Q _T and Q _G in the formula each represent the content (mass %) of the non-reducing sugar and moisturizing component with respect to the mass of the entire drug solution. The wet sheet according to claim 1, wherein the moisturizing component is glycerin. The wet sheet according to claim 1 or 2, wherein the non-reducing sugar is trehalose. The wet sheet according to any one of claims 1 to 3, wherein the constituent fibers of the fiber base material are water-absorbing fibers. The wet sheet according to any one of claims 1 to 4 , wherein the chemical solution contains at least one of polyaminopropyl biguanide and benzalkonium chloride. A chemical solution for wet sheets,
The drug solution contains protein, and further contains non-reducing sugars and moisturizing ingredients in a content that satisfies the following formula (1) or formula (2),
The drug solution, wherein the protein is denatured lysozyme .
When 0.50≦Q _G <1.50, Q _T ≧4.00 (1)
When 1.50≦ _QG , _QT ≧0.30...(2)
Note that Q _T and Q _G in the formula each represent the content (mass %) of the non-reducing sugar and moisturizing component with respect to the mass of the entire drug solution.